The recognition of tumor necrosis factor (TNF) as a key proinflammatory cytokine in Crohn’s disease (CD) and ulcerative colitis (UC) and the subsequent development of biologic drugs targeting TNF have redefined the management of inflammatory bowel disease (IBD). The gene discussed is TNF; the disease is ulcerative colitis.